Profil
Søren Nielsen is the founder of SynAct Pharma AB, which was founded in 2012.
He currently works as a Director at ApoGlyx AB.
Previously, he worked as the Chief Executive Officer at Action Pharma A.
Postes actifs de Søren Nielsen
| Sociétés | Poste | Début |
|---|---|---|
ApoGlyx AB
 ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Directeur/Membre du Conseil | - |
Anciens postes connus de Søren Nielsen
| Sociétés | Poste | Fin |
|---|---|---|
| SYNACT PHARMA AB | Fondateur | - |
Action Pharma A/S
 Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | President | 05/02/2010 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SYNACT PHARMA AB | Health Technology |
| Entreprise privées | 2 |
|---|---|
Action Pharma A/S
Action Pharma A/S BiotechnologyHealth Technology Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis. | Health Technology |
ApoGlyx AB
ApoGlyx AB BiotechnologyHealth Technology ApoGlyx AB engages in research and development of aquaporin inhibitors. It conducts sales of know-how, licenses, and chemical substance in biochemistry. The company was founded by Per Ola Kjellbom on April 22, 2008 and is headquartered in Lund, Sweden. | Health Technology |
